“Growing Adoption of Novel Therapies”
A key trend in the nephrology drugs market is the growing adoption of novel therapies, particularly SGLT2 inhibitors. These drugs, initially developed for diabetes, have shown promising results in managing chronic kidney disease (CKD) and preventing progression to end-stage renal disease (ESRD). SGLT2 inhibitors, such as empagliflozin and dapagliflozin, have been recognized for their ability to reduce proteinuria and improve kidney function in patients with CKD, even in those without diabetes. This class of drugs has gained significant attention due to their multifaceted benefits, including heart and kidney protection, which aligns with the increasing shift towards comprehensive, multi-disease treatments. The growing body of clinical evidence supporting their efficacy in slowing kidney disease progression is leading to their expanded use in nephrology. As a result, this trend is expected to drive market growth, with more drug approvals and greater uptake of these innovative therapies in treatment regimens.
